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ABSTRACT
Hot melt extrusion is a versatile continuous manufacturing process extensively investigated for its
applications with production of oral solid dosage forms, the aim of this study was to venture the
applicability of HME in continuous manufacturing of topical semi-solid ointment formulations.
Novel combination of a topical corticosteroid (Triamcinolone Acetonide) and local anesthetic
(Lidocaine hydrochloride) were selected to be formulated with a water-soluble ointment base
consisting of PEG 4000, PEG 1500 and Propylene glycol after performing appropriate drugexcipient compatibility studies. To determine the ratios of the solid to liquid components of the
macrogol base, ‘quality by design’ approach was employed by using design of experiments for
formulation selection. Three formulations were selected using texture (work of adhesion and
stiffness), pH and drug content uniformity as critical quality attributes from the design space of
the formulation. These three selected formulations were then produced by conventional fusion
method and simultaneously by HME using a modified screw configuration. Produced ointments
were subjected to further characterizations including texture analysis (work of adhesion and
stiffness), pH, drug content uniformity of the formulations, differential scanning calorimetry and
finally to exhibit the release profile of the formulation in vitro drug release testing was conducted.
All the final formulations depicted characteristics parallel to the set Quality Target Product Profile.
Moreover, Formulations prepared by HME displayed better texture, uniformity and drug release
characteristics in contrast with conventionally prepared ointments and hence HME can be
considered as a useful continuous manufacturing technique for semi-solid manufacturing.
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CHAPTER I: INTRODUCTION
Hot Melt Extrusion
Hot melt extrusion is one of the most widely utilized techniques in the Plastic industry. It involves
melting, mixing and conveying of raw materials using rotating twin screws at a suitable processing
temperature. The process results in production of uniformly shaped product propelled out of the
die[1]. HME has been exploited by several pharmaceutical industries and research groups for its
versatility in the manufacturing of pharmaceutical products[2][3]. The technique has found
application in production of amorphous solid dispersions for improving the solubility and hence
bioavailability of BCS class II API[4], formulation of abuse deterrent formulations[5][6], Taste
masking of geriatric and pediatric formulation[7][8], topical, trans dermal and trans mucosal drug
delivery systems[9][10][11]. A key aspect of this process is ‘continuous manufacturing’ which reduces
the time and resources invested in batch manufacturing and hence enhances the productivity and
in turn efficiency of the process. In this research project, a manufacturing process using HME for
the Continuous manufacturing of a topical semi-solid ointment formulation was optimized. To
accomplish this, certain attributes of Quality by Design (QbD) which are extensively suggested by
the regulatory bodies for a process or product development were used. Specifically, Design of
Experiments (DoE) which is a statistical tool used to apply QbD was used for this research project.
By employing HME for Ointment manufacturing several objectives were accomplished i.e.
Attaining a high yield and minimizing material loss experienced during conventional
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manufacturing, reducing the manufacturing time which in turn reducing the contact time of
thermolabile drugs with elevated temperature conditions and providing high shear and mixing
conditions which improves the texture and uniformity of the formulation of the formulations.
Active Pharmaceutical Ingredients
For this research a combination of a local corticosteroid (Triamcinolone acetonide) and a local
anesthetic (Lidocaine hydrochloride) which are responsible for the additive action against
inflammation were used. It has also been shown by previous research that Lidocaine HCl improves
the stability of Triamcinolone acetonide which enhances the shelf life of this combination[12].
Triamcinolone acetonide is a synthetic acetonide salt of triamcinolone which is a synthetic
glucocorticosteroid. The glucocorticoid mimicking is responsible for its immunosuppressive and
anti-inflammatory activity[13]. It controls or prevents inflammation by suppressing migration of
polynuclear leucocytes and fibroblasts and reversing capillary permeability. Corticosteroids
decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of
destructive acid hydrolases from leukocytes, inhibiting macrophage accumulation in inflamed
areas, reducing leukocyte adhesion to capillary endothelium, reducing capillary wall permeability,
reducing edema formation, decreasing complement components, antagonizing histamine activity,
antagonizing release of kinin from substrates, reducing fibroblast proliferation, collagen
deposition, and subsequent scar tissue
formation[14].
TAA is generally degraded into two main
degradation products i.e. 2-aldehyde and
17-carboxylic acid. Both are produced by
Figure 1. Structure of Triamcinolone acetonide
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oxidation reactions catalyzed by trace metals[15]. This makes 17-C substitution the main target for
TAA degradation. HME protects and minimizes the exposure of the product to oxygen because of
the enclosed processing conditions and minimal processing time. The Amide group present in
Lidocaine HCl might have a role in protecting the C-17 substitution from oxidation. Hence, Coformulation of the two involved APIs leads to improved anti-inflammatory activity and enhanced
stability of the formulation. The Melting range of TAA was found to be 273-275ºC which was
followed by the degradation of the API. Hence the processing temperature selected was below the
degradation temperature. The partial solubilization of TAA in the formulation gives sustained
release of the API at the site of inflammation and hence might provide an enhanced relief from
inflammation at the affected area.
Lidocaine hydrochloride is the Hydrochloride salt of the topical anesthetic Lidocaine, an
aminoethylamide and a prototypical member of the amide class anesthetics. Lidocaine interacts
with voltage-gated Na+ channels in the nerve cell membrane and blocks the transient increase in
permeability of excitable membranes to Na+. This prevents the generation and conduction of nerve
impulses and produces a reversible loss of sensation. Lidocaine hydrochloride also exhibits class
IB antiarrhythmic effects. The agent decreases the flow of sodium ions into myocardial tissue
especially on the Purkinje network during phase 0 of the action potential, thereby decreasing
depolarization, automaticity and excitability[16].
The melting point of LDH was found to be
73-75ºC and degradation temperature was
above

150ºC,

hence

the

processing

conditions were maintained below the
Figure 2. Structure of Lidocaine hydrochloride
degradation temperature to ensure the
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stability of the API. The solubility of LDH in Propylene glycol (aqueous phase) contributes to the
uniform distribution of the drug in the formulation and immediate release from the formulation on
application to give instant relieve from inflammation.
Design of Experiments
Quality is the measure of repeatability or reproducibility of a product or process in context with
its expressed attributes. The pharmaceutical Quality by Design (QbD) is a systematic approach to
development which begins with predefined objectives. It emphasizes on understanding product
and process control by using the sound science of quality risk management [17 ][18]. The quality
target product profile (QTPP) is generally accepted as a tool for setting the strategic foundation
for drug development. In the case of semisolids following parameters are considered critical for
the quality of the formulation [19][20].
Table 1. QTPP and CQA for 0.1% TAA and 2% LDH Ointment.
Elements
Dosage Form

Target
Ointment

Route of
Administration
Dosage strength
(TAA)
Dosage strength
(LDH)
Dosage design

Topical

Appearance

Identification
Assay

0.1%
2%
Water soluble ointment
with macrogol base with
completely soluble LDH
and partly soluble TAA
White, smooth, creamy
texture with API dispersed
in the cream base
Positive for API (TAA and
LDH)
90.0-110.0 %
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Justification
Proprietary product
requirements
Proprietary product
requirements
Proprietary product
requirements
Proprietary product
requirements
Based on the
physiochemical
properties of the
constituent API
Patient acceptability

CQA items

Needed for clinical
effectiveness
Needed for clinical
effectiveness

CQA
CQA

pH
Impurities

Homogeneity and
uniformity of
content

Physical attributes
Work of Adhesion

Between 6.2-6.8 for the
stability of the formulation
No known impurities;
unknown impurities NMT
0.2%; total impurities
NMT 0.2%
Samples withdrawn from
three regions of the
container should be within
90.0-110.0% of the label
claim

Stability and patient
acceptability
Needed for safety

CQA

Needed for clinical
effectiveness

CQA

Consistency in work of
adhesion to ensure
adherence of the
formulation to the skin

Needed for patient
acceptability and
optimum activity.

CQA

Patient acceptability

CQA

Needed for clinical
effectiveness and a
regulatory
requirement.
Clinical
effectiveness

CQA

Stiffness

In vitro release
testing

Stability

A function of viscosity;
should be consistent for
uniform manufacturing,
mass transfer and
application
Rate of release of the drug
with respect to the square
root of time
3 month accelerated
stability

CQA

Design of Experiments (DoE) is used to ensure the achievement of desired quality attributes in the
formulation. Various designs and statistical methods are usually considered for designing products
or processes. The variables in the product or process affecting the CQA can be determined and
optimized using this tool. For the current project DoE was used to optimize the formulation
components as they have a major effect on the physical attributes of the formulation i.e. work of
adhesion and stiffness. For this a 16 run, randomized, I-optimal design for mixtures was selected
as it gives a detailed idea of the interactions and effects of all the components in the
formulations[18]. The I-optimal design minimizes the average variances of prediction and therefore
5

seems more appropriate for mixture experiments as compared to the commonly used D-optimal
designs. Because I-optimal design provides minimum average variance and simultaneously
provides the effects of all the components in the formulation on the CQA. It was ideal to employ
it for this research project as the acquired data can be used for selection or prediction of optimized
combination of the components which demonstrate the required attributes.
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CHAPTER II: METHODOLOGY
Materials
Chemicals
Triamcinolone acetonide (Frontier Scientific, Batch no. LH20Q91), Lidocaine hydrochloride (MP
Biomedicals, LLC Batch no. Q9114), Polyethylene glycol 1500 (PEG 1500), Polyethylene glycol
4000 (PEG 4000), Propylene glycol, GantrezTM MS 955 Aerosil®, dibasic potassium phosphate,
monobasic sodium phosphate, dibasic sodium phosphate, HPLC grade Acetonitrile, Methanol and
Deionized water were used for analysis.
Equipment and auxiliaries
11 mm Twin screw extruder (ThermoFisher Scientific), Waters alliance e2695 HPLC separation
module and Waters 2489 UV system, Waters 600 controller, Waters 2487 UV/VIS detector,
Waters 717 plus autosampler, Mettler Toledo InLab®Micro pH probe, Texture Analyzer model
TA.XT2i (Texture Technologies Corp. /Stable Micro Systems) along with a 1-inch diameter (TA3), Cary 600 series Fourier transform infrared spectrometer, DSC (TA DSC 25), Varian 620-IR,
FT-IR Imaging microscope, Franz-diffusion cells, Hanson 15 Immersion cells with tools,
Phenomenex Luna® 5 µm C18(2) 100 Å, LC Column 250 x 4.6 mm, Hanson SR 8 plus dissolution
test station, Hanson small volume assembly.
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Methods
Drug-Excipient compatibility studies
Before proceeding to formulation development, it is of crucial importance to determine the Drug
Excipient compatibility i.e. the physical and chemical stability of the drug product with the
excipients on storage. Stability studies are usually performed to ensure the long-term stability of
the formulation but determination of the suitability of excipients as a part of Preformulation studies
is an essential part of formulation development. To determine the drug-drug and drug-excipient
compatibility binary mixtures of the drug substances with each component of the designed
formulations were prepared. For this 1:1 (w/w) ratio of drug-drug or drug-excipient were taken in
a glass mortar and pestle. This mixture was triturated for 5 minutes, vortexed and samples from
the bulk were analyzed using Cary 600 series Fourier transform infrared spectrometer, Agilent
technologies (FT-IR). The prepared mixtures as defined in Table 2 were then transferred to
scintillation vials and exposed to accelerated stability storage conditions (40±0.5ºC and 75±1
%RH) for one month using a validated stability chamber and then analyzed using FT-IR[21][22].
Table 2. Compositions of various vials exposed to accelerated stability storage conditions for the
determination of drug-drug/drug-excipient compatibility.
Vial code
*TAA
*
*
*
*
*

**LDH

***PEG
*

Components
Propylene glycol

GantrezTM

Aerosil®
1
2
*
3
*
4
*
5
*
6
*
*
7
*
*
8
*
*\
9
*
*
(*Triamcinolone acetonide, **Lidocaine hydrochloride, ***1:1 ratio of PEG 4000 to PEG 1500)
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Design of Experiments
Quality by Design (QbD) is a systematic approach to development (manufacturing, formulation
etc.) that begins with predefined objectives and emphasizes product and process understanding
and process control, based on sound science and quality risk management. For semi solid
formulations quality target profile includes parameters such as texture (work of adhesion,
Spreadibility, viscosity, stiffness etc.), pH of the formulation, drug content uniformity and to
prepare a formulation that fits all these requirements it is important to analyze the effects of
concentrations and ratios of different components on these parameters. For this an I-optimal
coordinate exchange, randomized, 16 runs design was selected which is ideal for mixtures using
design expert 11 software with fixed amounts of drugs and Aerosil® and varying proportions of
PEGs (PEG 1500 and PEG 4000), Propylene glycol and GantrezTM MS 955. These prepared
formulations with compositions mentioned in table 3 were exposed to preliminary screening using
Work of Adhesion, Stiffness and pH as response parameters such as texture and pH are the primary
and essential requirements in a semisolid topical formulation. Further in the design, formulations
F1 and F4; F2, F5 and F6; F9 and F10 have identical formulae which are introduced by the software
to determine point prediction, i.e. predictability of the characteristics of a formula based on results
obtained by the software. A design with good point prediction can help pinpoint exact amounts of
components required for desirable characteristics.
Table 3. I-optimal, coordinate exchange, randomized, 16 runs design with different compositions
PEG, PG and GantrezTM.
Formulation code
F1
F2
F3
F4
F5

*Propylene glycol (A)
20.00
38.70
54.80
20.00
38.70
9

PEG (B)
75.80
51.70
42.20
75.80
51.70

GantrezTM (C)
04.20
09.60
03.00
04.20
09.60

F6
38.70
51.70
09.60
F7
55.90
29.10
15.00
F8
31.90
65.10
03.00
F9
72.80
20.00
07.20
F10
72.80
20.00
07.20
F11
28.40
56.60
15.00
F12
65.40
31.60
03.30
F13
38.70
51.70
09.60
F14
45.50
39.50
15.00
F15
64.50
20.50
15.00
F16
20.00
65.00
15.00
(*represents 1:1 ratio of PEG 1500 and PEG 4000; all formulations had 0.1% Triamcinolone
acetonide and 2% Lidocaine hydrochloride which were fixed as per their prescription dose and
0.2% Aerosil®)
Manufacturing of selected formulations
The ointment was produced using two manufacturing processes i) Fusion method ii) Hot melt
extrusion.
Fusion method (Conventional)
All the required ingredients were carefully weighed and procured for preparation of the ointment.
First PEG 1500 and PEG 4000 were transferred into a glass mortar and pestle and triturated for 5
minutes. Then this mixture was transferred into a porcelain crucible which was placed on a hot
plate maintained at a temperature of 65±5ºC. Simultaneously, Aerosil®, GantrezTM, Triamcinolone
acetonide and Lidocaine hydrochloride were transferred into the liquid phase i.e. Propylene glycol
with appropriate mixing. On complete melting of PEG the liquid phase was fused with it and this
mixture was maintained at 65±5ºC for 5 minutes to equilibrate the temperature of the mixture. This
mixture was transferred to a glass mortar and pestle and triturated until solidification and
appearance of a clicking sound. The semisolid mass was then transferred into Ointment containers
and stored under refrigerated conditions for further use.
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Hot-melt extrusion (continuous manufacturing process)
For the manufacturing of ointment with HME first, the volumetric feeder (Solid feed) and the
peristaltic pump (liquid feed) were calibrated by preparing a calibration curve of weight dispensed
per minute vs % output (feeder parameter) and weight dispensed per minute vs RPM of peristaltic
pump. A modified screw design was selected for the processing of the ointment through HME[10].

Figure 3. Modified screw design for manufacturing of the ointment formulation.
The liquid feed was introduced from zone 3 of the 11 mm hot melt extruder (ThermoFisher
scientific, 11 mm twin screw extruder). The screw design was modified (as shown in fig. 3) in
such a way that the liquid feed and the solid feed were exposed to proper mixing by the
incorporation of an extended mixing zone followed by a material conveying zone and a terminal
mixing zone before ejection of the processed semisolid into the collecting unit. The physical
mixtures of PEG 1500, PEG 4000, GantrezTM, Aerosil®, Triamcinolone acetonide and Lidocaine
hydrochloride were prepared and introduced at a predetermined feed rate depending on the ratio
of liquid to solid feed. Propylene glycol was introduced in zone 3 after 1 minute and 23 seconds
(time taken for solid feed to reach zone 3 with an RPM of 100) of introducing solid feed.
11

Table 4. Processing parameters maintained for the manufacturing of ointment by Hot melt
extrusion.
Parameters
Equipment
Screw design
Barrel temperature

Description
Pharma 11mm twin screw extruder
Modified
Zone 1-5 (65ºC)
Zone 5-8 (40ºC)
100
0-3%

RPM
Torque
pH

pH of the skin is considered to be around 5.5 and hence acceptable semisolid formulations should
have a pH ranging from 5.5-7.0 to be compatible with the skin. To determine the pH aqueous
concentrations of 1%, 5% and 10% w/v of the ointments were prepared in water[10]. The pH of the
solutions was analyzed using Mettler Toledo InLab®Micro pH probe (Electrolyte 3 mol/L KCl).
pH was considered as a critical quality attribute for the screening of the ointments.
Texture analysis
For texture analysis, Texture Analyzer model TA.XT2i (Texture Technologies Corp. /Stable Micro
Systems) along with a 1-inch diameter (TA-3), acrylic, cylindrical probe, and a soft matter kit (TA275) was used for the determination of texture properties i.e. the work of adhesion and stiffness[11]
using the parameters mentioned in table 5. Soft matter fixture was filled with the product, and it
was placed below the texture analyser’s probe. The test was performed by lowering the probe at
the pre-test speed to the product surface. The probe produced an additional deformation of 2mm
of the sample at the test speed of 0.50 mm/s after encountering the surface and sensing the trigger
force. The probe then withdrew from the sample at the speed of 5.00 mm/s. The same procedure
was repeated for each sample in triplicates after cleaning the probe and levelling the surface of the
sample. These two parameters are a representative of the force required by the probe to penetrate
12

the mass of the sample semisolid (Stiffness) and the force and time required for the probe to
withdraw from this mass of ointment (work of adhesion) which are recorded as peak positive force
and area of the negative slope respectively.
Table 5. Parameters and set values for the texture analysis of prepared semisolid formulations.
Parameters
Test mode
Pre-test speed
Test speed
Post-test speed
Target mode
Force
Distance
Trigger type
Trigger force
Hold time
Temperature

Set values
Compression
0.50 mm/sec
0.50 mm/sec
5.00 mm/sec
Distance
100.0 g
2 mm
Auto
5g
5 sec
Room temperature

Drug-content uniformity
Drug content uniformity was determined by dispersing 100 mg (Triamcinolone acetonide)
equivalent of the sample withdrawn from three different regions of the ointment container into 100
ml of Acetonitrile (common solvent for extraction Triamcinolone acetonide and Lidocaine
hydrochloride) and this mixture was subjected to sonication to facilitate the solubilization of the
API in the solvent [20]. After sonication the solution was subjected to centrifugation and 10 µl of
aliquot was withdrawn and diluted up to 1 ml with Acetonitrile. The concentration was analyzed
using Waters HPLC-UV (Waters corp.) system. For the analysis calibration curve of
Triamcinolone ranging from 5-80 µg/ml and of Lidocaine hydrochloride ranging from 50-800
µg/ml were used.
Method of analysis
For the analysis of Triamcinolone acetonide and Lidocaine hydrochloride simultaneously, Waters
13

alliance e2695 HPLC separation module and Waters 2489 UV system was used. An existing
method was modified[23], and the modified method was evaluated for its Capacity Factor,
Selectivity and Resolution[24]. Table 6 displays the parameters for the HPLC method used for the
simultaneous measurement of the drug substances.
Table 6. Parameters for the modified HPLC method.
Parameters
Mobile Phase

Set values
*Phosphate buffer (pH 6.8): Acetonitrile:
Methanol (50:40:10)
LC-18-DB, Stainless steel, 250 mm X 4.6
mm, 5µ particle size
20 µl
**238 nm and 210 nm for Triamcinolone and
Lidocaine respectively
1 ml/min

Column
Injection volume
Detection wavelength

Flow rate
Retention time
Lidocaine hydrochloride
6.4 minutes
Triamcinolone acetonide
8.9 minutes
Run time
12 minutes
*prepared by adding 8.75 g of dibasic potassium phosphate in 1000 ml of water and the adjusting
pH with O-phosphoric acid.
**For instruments with two detector channels two wavelengths can be used for better limit of
detection of Lidocaine hydrochloride. For single detector channels wavelength of 238 nm should
be used.
Differential scanning calorimetry
Differential scanning calorimetry presents various exothermic and endothermic events occurring
in the sample with an increase in temperature. These events could represent Tm (Melting point of
crystalline substances), Tg (Glass transition of amorphous polymers), Polymorphism and
degradation. For this study the DSC (TA DSC 25) of PEG (1500 & 4000), Gantrez, Triamcinolone
acetonide and Lidocaine hydrochloride at a ramp rate of 10ºC /min with the temperature ranging
from 25ºC to 300ºC[10][11] was conducted. Followed by the generation of DSC profiles of these
individual components, DSC of the formulations were performed to observe any degradation peaks
14

and assess the solubilization of the drug in formulation with a ramp rate of 20ºC/min to avoid the
distortion of peaks due to the presence of Aerosil® in the formulation and the same heating range.
In vitro release testing (IV-RT)
In vitro release testing (IV-RT) is a critical quality attribute for semi-solid formulations which
predicts the release kinetics of the drug substance from the product. For this study vertical Franzdiffusion cells were used with suitable receiver media and release membrane. The protocol for
release studies was optimized using the following procedure and steps[27].
Drug solubility studies
To determine the composition of the release media, saturation solubilities of Triamcinolone
acetonide was determined by mixing 10 mg of the drug substance in 2 ml of various aqueous media
(mentioned in table 7) with varying composition using 2 ml centrifuge tubes (n=3). These mixtures
were transferred to a mechanical shaker and subjected to continuous agitation at a rate of 70 RPM
for 24 hours. Later the samples were subjected to centrifugation at 13000 RPM for 10 minutes.
The supernatant was collected and transferred to HPLC vials for analysis. The concentration was
determined using the mentioned method of analysis. Solubility studies for Lidocaine HCL were
not necessary as the drug substance was freely soluble in all considered medias[26].
Table 7. Composition of various vials for solubility studies
Sample no.
1 (a, b, c)
2 (a, b, c)
3 (a, b, c)
4 (a, b, c)
5 (a, b, c)
6 (a, b, c)
7 (a, b, c)
8 (a, b, c)
*9 (a, b, c)

Composition
Milli Q water
**0.1 M Phosphate buffer solution (pH 7.4)
0.1 % v/v Tween 60
0.1 % v/v PEG 400
0.1 % w/v BrijTM 98
0.1 % w/v BrijTM C-20 SO (AP)
0.1 % w/v BrijTM S-20 SO (mM)
0.1 % v/v BrijTM L4 LQ (AP)
0.2 % w/v BrijTM C-20 SO (AP) in PBS
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*10 (a, b, c)
0.2 % w/v BrijTM S-20 SO (mM) in PBS
*11 (a, b, c)
0.2 % v/v BrijTM L4 LQ (AP) in PBS
*These samples were a part of the secondary screening for selection of the receiver media rest of
the samples were used for preliminary screening.
**0.1M PBS was prepared using Monosodium Phosphate, monohydrate (2.795g/l) and Disodium
Phosphate, heptahydrate (21.37g/l).
Membrane inertness testing
This study was performed to select a membrane suitable for the release studies. For this study drug
solutions of Triamcinolone acetonide (5µg/ml), Lidocaine hydrochloride (5µg/ml) and a
combination of Triamcinolone acetonide & Lidocaine hydrochloride (5µg/ml) were prepared. 10
ml of each solution was taken in centrifuge tubes and labelled respectively as described in table 8.
Four selected membranes were cut into half. 0.5 ml of sample was withdrawn from the centrifuge
tube before soaking the membrane. Then the membrane was soaked in the centrifuge tube and
allowed to soak for 24 hours. After 24 hours, 1 ml of sample was withdrawn from each of the
centrifuge tubes and the before and after samples were analyzed using HPLC. A suitable inert
membrane would not absorb the drug from the drug solution. This study is performed to ensure no
retention of the drug on the membrane during the release studies.
Table 8. Composition of various sample tubes taken for analysis with respective membranes
used for the membrane inertness studies.
Sample no.
1
2
3
4
5
6
7
8
9
10
11

Membrane
Nylon
Sopor
Tuffryn
Cyclopore
Nylon
Sopor
Tuffryn
Cyclopore
Nylon
Sopor
Tuffryn

Pore size
0.22 µm
0.20 µm
0.45 µm
0.20 µm
0.22 µm
0.20 µm
0.45 µm
0.20 µm
0.22 µm
0.20 µm
0.45 µm

Diameter
47 mm
25mm
25 mm
25 mm
47 mm
25mm
25 mm
25 mm
47 mm
25 mm
25 mm
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Drug solution (5 µg/ml)
TAA
TAA
TAA
TAA
LDH
LDH
LDH
LDH
TAA+LDH
TAA+LDH
TAA+LDH

12
Cyclopore
0.20 µm
25 mm
TAA=Triamcinolone acetonide; LDH=Lidocaine hydrochloride

TAA+LDH

Membrane validation studies
Three ointment formulations were prepared with the drug load of 50%, 100% and 200% of the
label claim (0.1% Triamcinolone acetonide and 2% Lidocaine hydrochloride) and the membrane
validation studies were performed using Franz-diffusion cells (1.77cm2). Rubber rings were used
to mount the membrane, the receiver compartment was filled with 7 ml of suitable receiver media
and a stir bar was inserted in the cell to facilitate diffusion. Before initiating the studies, the selected
membrane was soaked in the release media for 30 minutes and then mounted on the cell. Weighed
amounts of the ointment formulations were withdrawn and placed on the donor compartment
above the membrane and the sample was covered with parafilm, the assembly of the cell is shown
in fig.4. Receiver compartment was checked for air bubbles. 0.3 ml of the sample was drawn at
six different timepoints (0.5, 1, 2, 3, 4, 5 hours) and analyzed in HPLC. This experiment was
performed using 9 cells (n=3).

Figure 4. assembly of a vertical Franz-diffusion cell[28].
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Table 9. Weight of the formulations placed in the individual cells
Cell number
1
2
3
4
5
6

Drug load (%)
50
100
200
50
100
200

Weight of the sample (grams)
0.75
1.06
1.05
0.95
0.83
0.84

Drug release testing
After performing the solubility studies (to determine the release media), membrane inertness
testing (to screen a suitable inert membrane) and membrane validation studies (to ensure that the
membrane does not act as a rate limiting barrier), the release studies of the three optimized
formulation prepared by both conventional and HME process were performed. Immersion cells
(Hanson, 15 mm) and 150 ml capacity dissolution cells were employed to determine the release of
the drugs from the formulations. Immersion cells can be used as an automated quality control tool
in the in vitro release testing procedure as a modification of USP II dissolution apparatus (paddle
type)[29]. To load the immersion cells with ointment, first the support ring was placed upside down
(larger opening face up) and then the membrane was locked in between the orifice washer and the
ointment washer in a way that the membrane has minimum wrinkles. The dose was then applied
to the circular area in the middle of the ointment washer and spread evenly. The ‘O’ ring was
placed on the washer and the glass washer was placed to seal the ointment compartment. The lock
ring was then placed on the support ring and sealed using the hand tool. These immersion cells
loaded with ointment formulations were then immersed in the dissolution vessels (inserted in the
dissolution apparatus using a conversion kit) with 150 ml of receiver media. Suitable paddles were
introduced to the cell and the temperature was adjusted to 32±0.1ºC (temperature of the skin). 1
ml of the sample was isolated and replaced with media at pre-determined time points (0.5, 1, 2, 3,
18

4 and 5 hours). The collected samples were then estimated using the developed HPLC method for
this combination of drug substances.
a

b

Figure 5. a) Assembly of the dissolution apparatus and immersion, b) Packing of ointment into
the immersion cell[30]
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CHAPTER III: RESULTS AND DISCUSSION
Drug-Excipient compatibility
The binary mixtures prepared were exposed to FT-IR analysis to determine the physical (Hbonding) or chemical interactions between API and Excipients.

Figure 6. FT-IR of Triamcinolone acetonide with various excipients
From fig. 6 it can be seen that triamcinolone has prominent peaks on 3330 cm-1 which is because
of the ‘-OH’ stretching vibrations[31]. This is an important site of reaction and degradation for
triamcinolone and the intactness or slight shift in the peak shows no or weak physical interactions
in the compounds. Weak physical interactions like H-bonding are responsible for increasing the
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solubility and stability of the API in the formulation. It can be observed in excipients like PEG and
PG having ‘-OH’ groups and interacting with the concerned API. A similar interaction was visible
between TAA and LDH which could be the reason for enhanced stability of the API in presence
of TAA. The potency of the API was retained after subjecting the binary mixtures for a 1-month
accelerated stability which ensures the compatibility of the API with the selected excipients.
Aerosil® displays strong intermolecular H-bonding which is responsible for the disappearance of
the ‘-OH’ peak in the binary mixture.

Figure 7. FT-IR of Lidocaine hydrochloride with various excipients
Fig. 7 shows the interactions of various excipients with LDH and similar to TAA, the potency of
LDH remains the same after storage with the excipients. The FT-IR shows that LDH is having
weak interactions with PEG, PG and Aerosil® which seem like weak H-bonding that don’t affect
the stability of LDH but enhance the solubilization of LDH in the formulation. This is the reason
for complete solubilization of LDH in the formulation.
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Screening of formulations
The preliminary screening was performed based on CQA(s) like Texture (work of adhesion,
stiffness) and pH of the formulation as mentioned in table 10.
Table 10. Preliminary screening of the formulations based on CQA
Formulation code
F1
F2
F3
F4
F5
F6
F7
F8
F9
F10
F11
F12
F13
F14
F15
F16

Work of adhesion
529.28
420.78
147.03
550.00
452.80
465.32
049.68
597.21
020.73
028.55
460.58
050.39
473.44
162.87
027.76
650.61

Stiffness
3823.2
0834.7
0202.7
3820.0
0814.8
0792.6
0056.4
1059.8
0030.4
0021.9
0826.5
0051.9
0750.3
0193.4
0035.6
2038.2

pH
6.04
6.11
6.05
6.25
6.12
6.11
5.99
6.21
6.13
6.13
5.98
6.33
6.12
5.92
6.03
5.98

All the formulations had a varying ratio of PEG:PG:GantrezTM and on analyzing the statistics it
was seen that there is a significant correlation between the components and their ratios on the
work of adhesion and stiffness.
Work of Adhesion
Table 11. ANOVA of the tested formulation for work of adhesion
Source
Model
Linear Mixture
AB
AC
BC
Residual

Sum of
Squares
24.40
21.98
01.53
00.34
00.43
00.26

DF
05
02
01
01
01
10

Mean
Square
04.88
10.99
01.53
00.34
00.43
00.03
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F-Value

P-Value

Significance

189.01
425.67
059.37
013.24
016.66

< 0.0001
< 0.0001
< 0.0001
0.0045
0.0022

significant

Lack of Fit

00.19

05

00.04

Pure Error
Cor Total

00.06
24.66

05
15

00.01

03.30

0.1082

not
significant

Table 11 provides information about the impact of the ratios of the components on the work of
adhesion of the formulation. The Model F-value of 189.01 implies the model is significant. There
is only a 0.01% chance that an F-value this large could occur due to noise. P-values less than
0.0500 indicate model terms are significant. In this case A, B, C, AB, AC, BC are significant
model terms. Values greater than 0.1000 indicate the model terms are not significant. The Lack
of Fit F-value of 3.30 implies that the Lack of Fit is not significant relative to the pure error.
There is a 10.82% chance that a "Lack of Fit F-value" this large could occur due to noise. Nonsignificant lack of fit is good as it displays that the model to fits.
Table 12. Fit statistics for the design
Fit statistics
Std. Dev.
Mean
C.V. %

0.16
5.23
3.07

R²
Adjusted R²
Predicted R²
Adeq Precision

00.9895
00.9843
00.9689
32.9603

Table 12 shows that the Predicted R² of 0.9689 is in reasonable agreement with the Adjusted
R² of 0.9843; i.e. the difference is less than 0.2. Adeq Precision measures the signal to noise ratio.
A ratio greater than 4 is desirable. The ratio of 32.960 indicates an adequate signal and hence the
model can be used to navigate the design space.
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Table 13. Coefficients in terms of coded factors
Component
A-PG
B-PEG
C-Gantrez
AB
AC
BC

Coefficient
Estimate
02.71
06.25
-19.64
03.78
30.60
33.72

df
1
1
1
1
1
1

Standard
Error
0.1596
0.1202
6.5300
0.4903
8.4100
8.2600

95% CI
Low
02.36
05.98
-34.18
02.69
11.86
15.31

95% CI
High
03.07
06.51
-05.10
04.87
49.33
52.12

VIF
004.37
002.88
473.40
002.66
190.38
184.09

The coefficient estimate (Table 13) represents the expected change in response per unit change in
factor value when all remaining factors are held constant. The intercept in an orthogonal design is
the overall average response of all the runs. The coefficients are adjustments around that average
based on the factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1
indicate multi-collinearity, the higher the VIF the more severe the correlation of factors. As a rough
rule, VIFs less than 10 are tolerable.

Figure 8. Two component mix plots with varying ratios of PEG and PG in the formulations
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Figure 9. Predicted versus actual values of work of adhesion for the formulations
Stiffness
Table 14. ANOVA of the tested formulations for stiffness
Source
Model
Linear
Mixture
AB
AC
BC
Residual
Lack of Fit

Sum of
Squares
45.4100

df Mean Square

F-value

p-value

Significance

05

09.0800

306.07

< 0.0001

significant

44.6500

02

22.3200

752.29

< 0.0001

00.1236
00.5791
00.5966
00.2968

01
01
01
10

00.1236
00.5791
00.5966
00.0297

004.17
019.52
020.11

0.0686
0.0013
0.0012

00.2361

05

00.0472

003.89

0.0811

not
significant

Pure Error
00.0607
05
00.0121
Cor Total
45.71
15
The Model F-value of 189.01 (Table 14) implies the model is significant. There is only a 0.01%
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chance that an F-value this large could occur due to noise. P-values less than 0.0500 indicate model
terms are significant. In this case A, B, C, AB, AC, BC are significant model terms. Values greater
than 0.1000 indicate the model terms are not significant. The Lack of Fit F-value of 3.30 implies
the Lack of Fit is not significant relative to the pure error. There is a 10.82% chance that a "Lack
of Fit F-value" this large could occur due to noise. Non-significant lack of fit is good as it displays
that the model to fit.
Table 15. Fit statistics for the design

Std. Dev.
Mean
C.V. %

Fit statistics
R²
Adjusted R²
Predicted R²
Adeq Precision

0.1723
5.8200
2.9600

00.9935
00.9803
00.9791
46.4605

The Predicted R² of 0.9689 shown in table 15 is in reasonable agreement with the Adjusted R² of
0.9843; i.e. the difference is less than 0.2. Adeq Precision measures the signal to noise ratio. A
ratio greater than 4 is desirable. The ratio of 32.960 indicates an adequate signal. This model can
be used to navigate the design space.
Table 16. Coefficients in terms of coded factors
Component
A-PG
B-PEG
C-Gantrez
AB
AC
BC

Coefficient
Estimate
02.72
08.12
-26.06
01.07
39.83
39.71

df
1
1
1
1
1
1

Standard
Error
0.1711
0.1289
7.0000
0.5257
9.0100
8.8600

95% CI
Low
02.3400
07.8300
-41.6500
-00.0985
19.7400
19.9800

95% CI
High
03.10
08.41
-10.47
02.24
59.91
59.44

VIF
004.37
002.88
473.40
002.66
190.38
184.09

The coefficient estimates in table 16 represents the expected change in response per unit change
in factor value when all remaining factors are held constant. The intercept in an orthogonal design
is the overall average response of all the runs. The coefficients are adjustments around that average
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based on the factor settings. When the factors are orthogonal the VIFs are 1; VIFs greater than 1
indicate multi-collinearity and the higher the VIF the more severe the correlation of factors. As a
rough rule, VIFs less than 10 are tolerable.

Figure 10. Two component mix plots with varying ratios of PEG and PG in the formulations
fig 10. Shows that stiffness of the formulation increases with an increase in the PEG concentration.
This shows that the PEG and the PG concentrations have a significant effect on the stiffness of the
formulation. Moreover formulation concentration for a desired stiffness can be predicted using the
software because of the high degree of regression and fit statistics displayed in table 15 and fig 11.
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Figure 11. Actual versus Predicted plot for the values of stiffness for various prepared
formulations
pH
The pH of all the prepared formulations were within range. Though pH is considered as a CQA
for this formulation and will be used for evaluation of the formulations, it was no longer considered
a parameter for screening of the formulations as there was no significant correlation between the
ointment components and pH.
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Analytical Method Validation
Four major descriptors are commonly used to report the characteristics of the chromatographic
column, system and particular separation i.e. Retention factor/Capacity factor (k’), selectivity (α)
and Resolution.
Length of time taken by the retarded compound to pass through the column depends on its capacity
factor. It is the measure of degree to which an analyte partitions into the stationary phase from the
mobile phase. This can be determined by using the following equation where tr is the retention
time of the analyte and t0 is the retention time of the non-retained sample i.e. solvent front.
𝑘′ =

𝑉𝑟 − 𝑉0
𝑉0

𝑘 ′ = (𝑡𝑟 − 𝑡𝑜 )/𝑡0
The capacity factor for TAA (k’TAA) was found to be 4.99 (solvent front was seen at 1.5 minutes
and retention time of TAA is 8.99 minutes), for LDH (k’LDH) was found to be 3.26 (retention time
of LDH was observed to be 6.4 minutes). A capacity factor between 1-5 is ideal for analysis.
Selectivity (α) is the ability of the chromatographic system to discriminate between the two
analytes and can be determined by taking a ratio of the capacity factors of the two analytes.
∝=

𝑘𝑇𝐴𝐴
𝑘𝐿𝐷𝐻

α for the system was found to be 1.53 which is ideal for uninterrupted determination of two
analytes.
Finally, resolution of the system was determined using the following formulae.
𝑅=2

𝑡𝑇𝐴𝐴 − 𝑡𝐿𝐷𝐻
𝑤1 + 𝑤2

The resolution of system should be ≥1.5 and the resolution for this system was found to be 6.4
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which is an excellent resolution for determination.
Optimization and Manufacturing processes
After preliminary screening of the formulations, three formulations (F2, F3 and F8) with desirable
properties were selected (Table 17) , manufactured using conventional and HME techniques and
characterized for Uniformity of Drug Content, Differential Scanning Calorimetry, Hot Stage
Microscopy and in vitro release testing.

SOLID
FEED
LIQUID
PHASE

Figure 12. Manufacturing process of Ointment formulations using HME
Three formulations were selected for further characterization with different Stiffness and Work of
Adhesion depending on the purpose of use. Formulation F2 was selected and intended for oral use
i.e. ulcers, burns etc. Formulation F3 was selected for skin infections, burns and allergic
manifestations because of better Spreadibility and Formulation F8 was selected for Hemorrhoids
treatment because of its stiff and adhesive nature which enhances the retention time of the
formulation and delays softening of the formulation which improves therapeutic efficiency and
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patient compliance.
Table 17. Selected formulations and their characteristics.
Formulation
code

Work of
Adhesion

Stiffness

F2C
498.223±52.988 0843.5600±30.67
F2H
488.618±03.550 0865.4445±03.15
F3C
159.808±27.460 0228.4200±25.77
F3H
148.372±03.450 0215.5470±02.02
F8C
615.104±68.780 1230.4500±80.26
F8H
596.154±08.920 1014.6400±06.12
C-Conventionally prepared; H-Hot-Melt Extruded.

pH

6.11±0.04
6.22±0.01
6.05±0.07
6.27±0.05
6.21±0.03
6.30±0.03

Drug
Content
(TAA)
098.9±0.017
104.7±0.008
108.5±0.002
101.5±0.003
095.3±0.010
094.8±0.006

Drug
Content
(LDH)
107.9±1.018
108.4±0.999
106.6±0.954
097.7±0.890
101.3±1.090
101.9±0.988

From the above characterization of selected formulations, it can be observed that conventionally
prepared ointments have a larger standard deviation as compared to the ointments prepared using
HME. This could be due to the uncontrolled variables that participate in conventional
manufacturing such as material loss during mixing, mass transfer, rate of mixing or temperature
control during mixing which are in fact very well controlled during HME processing. During the
Hot Melt Extrusion process, parameters such as feed rate, mixing RPM, processing temperature
and torque are well under control which helps produce uniform products and minimize batch to
batch variation. The pH of all the formulations (HME and Conventional) was within the specified
range. All the formulations had drug content within the specified range and hence all the produced
Ointments were accepted and subjected to further characterization.
Differential scanning calorimetry
All the prepared Ointments were characterized using DSC to ensure the solubility of the API in
the formulation. The DSC plot shows complete disappearance of the drug peaks which suggests
that either both the drugs have been dissolved in the base or that the increase in temperature during
DSC experimentation has solubilized the drugs in the base. From the DSC curve shown in Fig. 13,
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it can be seen that there has been complete solubilization of the drugs in the Ointment base both
in

HME and Conventionally prepared ointments.
Figure 13. DSC profiles of pure API, excipients and prepared Ointment formulations.
In vitro release testing (IV-RT)
Based on the saturation solubility of TAA in various release media, 0.2 % w/v BrijTM C-20 SO
(AP) in PBS was selected as it completely solubilized LDH and had the maximum solubility for
TAA (Table 18) with respect to the other tested release mediums with different surfactants.
Table 18. Solubilities of TAA in different release mediums.
Sample number
1
2
3
4
5
6
7
8
9

Solubility (µg/ml)
Practically insoluble
Practically insoluble
3.65
Practically insoluble
3.44
7.71
7.30
6.74
9.08
32

10
6.63
11
8.45
Refer Table 7 for sample compositions
Tuffryn 0.45µm, 25mm membrane was selected amongst the tested membranes because of its
inertness to the API. There was negligible absorption of API on the membrane before and after
exposure to the drug solution.
Table 19. Membrane inertness studies.
Sample number
% Absorbed (TAA)
1
4.20
2
2.89
3
0.72
4
2.44
5
6
7
8
9
0.73
10
0.43
11
0.14
12
3.21
Refer Table 8 for sample composition

% Absorbed (LDH)
0.19
0.59
0.19
0.19
0.19
0.39
0.19
0.58

From the other values it can be seen that the Tuffryn membrane absorbed the least amount of
TAA and LDH from the drug solution which makes its use suitable for this study.
Finally, to see if the release of the API from the formulation is not hindered by the membrane
and is proportional to the concentration of the drug in the formulation, membrane validation
studies were conducted.
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Figure 14. Membrane validation for TAA
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Figure 15. IV-RR versus dose strength of TAA
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250

The membrane validation studies were performed using the topical product prepared at three
strengths (50% of the label claim, 100% label claim and 200% label claim). The release profile
(cumulative release versus square root of time) showed a linear profile as shown in figure 14 and
16. Figures 15 and 17 shows the relationship between the dose strength and IV-RR (Slope of
cumulative release versus square root of time). Liner correlation with excellent regression
coefficient (>0.9) shows that the membrane could be used for performing the release studies of
other formulations or form comparison of the formulated product with the reference product. The
membrane is not acting as a rate controlling barrier and the release is absolutely attributable to the
formulation properties.
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Figure 16. Membrane validation of LDH
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Figure 17. IV-RR versus Dose strength of LDH
Finally using the above selected release media, membrane release studies of the selected
formulations were performed. It can be seen from the release studies that the formulations prepared
by HME and the formulations prepared conventionally show comparable release rates. Moreover,
formulations F2 and F8 show better release rates and profiles as compared to conventionally
prepared formulation. This can be attributed to the enhanced and uniform mixing provided by HotMelt extrusion which allows proper distribution and enhanced solubilization of TAA in the
ointment base which is not achieved conventionally. F3H exhibits a similar release profile as
compared to F3C, this could be because of a higher drug content in F3C as compared to F3H.

36

F2 TAA Drug release
100.00
R² = 0.9642

µg/cm2

80.00
60.00

R² = 0.9901

40.00
20.00
0.00
0.00

0.50

1.00

1.50

2.00

2.50

√Time
F2 Conventional TAA

F2 HME TAA

Linear (F2 Conventional TAA)

Linear (F2 HME TAA)

Figure 18. Drug release profile of TAA from F2H and F2C
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Figure 19. Drug release of LDH from F2H and F2C
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Figure 20. Drug release profile of TAA from F3H and F3C
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Figure 21. Drug release profile of LDH from F3H and F3C
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Figure 22. Drug release profile of TAA from F8H and F8C
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Figure 23. Drug release profile of LDH from F8H and F8C
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CHAPTER IV: CONCLUSION
A series of statistical and experimental characterizations were conducted to optimize the
formulation and manufacturing variables for the production of three stable Ointment formulations.
Drug-Excipient compatibility studies demonstrated the absence of drug-drug and drug-excipient
interactions. Further, the I-optimal design provided a design space and platform which can be used
for prediction of the excipient ratios for a target texture profile. Selected formulations were
successfully manufactured using conventional and HME techniques. From the results of
comparison between the conventional and HME ointment formulations, it can be concluded that
HME shows a better control over the process variables and leads to the production of a more
uniform product. It can also be concluded that the controlled processing variables lead to a reduced
batch to batch variation and improved the consistency in the CQA(s) of the ointments.
Simultaneously, a protocol to evaluate the in vitro release rates of formulations containing either
TA, LDH or both were successfully developed and validated.
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